MedTrace Logo

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

NCT01442194 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3076

Last updated 2022-01-14

No results posted yet for this study

Summary

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Conditions

Interventions

DRUG

other disease-modifying therapy

DRUG

Fingolimod

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2020-07-10
Completion
2020-07-10

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Chile
  • Mexico
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442194 on ClinicalTrials.gov